Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose naltrexone for induction of remission in mild to moderate Crohn's disease after failure of conventional treatment
NL-OMON21939Recruiting
- Sponsor
- ZonMw
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of naltrexone in Crohn's disease (3 arms), sponsored by ZonMw. Started Nov 2020; status: recruiting.
02
Drugs
naltrexone
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON21939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21939.